pMXs-hu-N-Myc Citations (4)

Originally described in: Promotion of direct reprogramming by transformation-deficient Myc.
Nakagawa M, Takizawa N, Narita M, Ichisaka T, Yamanaka S Proc Natl Acad Sci U S A. 2010 Jul 26. ():. PubMed Journal

---

Articles Citing pMXs-hu-N-Myc

Articles
Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma. Dalton KM, Krytska K, Lochmann TL, Sano R, Casey C, D'Aulerio A, Khan QA, Crowther GS, Coon C, Cai J, Jacob S, Kurupi R, Hu B, Dozmorov M, Greninger P, Souers AJ, Benes CH, Mosse YP, Faber AC. Mol Cancer Ther. 2021 Aug;20(8):1400-1411. doi: 10.1158/1535-7163.MCT-20-0710. Epub 2021 Jun 4. PubMed
MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma. Floros KV, Chawla AT, Johnson-Berro MO, Khatri R, Stamatouli AM, Boikos SA, Dozmorov MG, Cowart LA, Faber AC. Cell Stress. 2022 Jan 17;6(2):21-29. doi: 10.15698/cst2022.02.264. eCollection 2022 Feb. PubMed
Targeting TRIM24 promotes neuroblastoma differentiation and decreases tumorigenicity via LSD1/CoREST complex. Shi Q, Yu B, Zhang Y, Yang Y, Xu C, Zhang M, Chen G, Luo F, Sun B, Yang R, Li Y, Feng H. Cell Oncol (Dordr). 2023 Jul 19. doi: 10.1007/s13402-023-00843-4. PubMed
Direct reprogramming of non-limb fibroblasts to cells with properties of limb progenitors. Atsuta Y, Lee C, Rodrigues AR, Colle C, Tomizawa RR, Lujan EG, Tschopp P, Galan L, Zhu M, Gorham JM, Vannier JP, Seidman CE, Seidman JG, Ros MA, Pourquie O, Tabin CJ. Dev Cell. 2024 Feb 5;59(3):415-430.e8. doi: 10.1016/j.devcel.2023.12.010. PubMed

If you have published an article using this material, please email us at to have your article added to this page.